Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Candel Therapeutics, Inc. (CADL) had Consolidated Net Income/Loss of $7.38M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$7.38M |
|
-- |
|
-- |
|
$8.13M |
|
$-8.13M |
|
$15.51M |
|
$7.38M |
|
$7.38M |
|
$7.38M |
|
$7.38M |
|
|
Consolidated Net Income/Loss |
$7.38M |
$7.38M |
|
$-8.13M |
|
$-7.88M |
|
50.48M |
|
54.77M |
|
$0.15 |
|
$0.13 |
|
| Balance Sheet Financials | |
$93.15M |
|
$1.97M |
|
$2.76M |
|
$95.91M |
|
$20.07M |
|
$0.90M |
|
$1.16M |
|
$21.23M |
|
$74.67M |
|
$74.67M |
|
$74.67M |
|
49.25M |
|
| Cash Flow Statement Financials | |
$-8.62M |
|
$-0.00M |
|
$-1.87M |
|
$102.92M |
|
$92.43M |
|
$-10.49M |
|
$0.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.64 |
|
-- |
|
-- |
|
0.01 |
|
0.13 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.62M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
9.88% |
|
9.88% |
|
7.69% |
|
9.76% |
|
$1.52 |
|
$-0.16 |
|
$-0.16 |
|